The trial focuses on the safety and tolerability study of BR01T, a groundbreaking monoclonal antibody designed to target Tropomyosin Receptor Kinase (TrkA) for addressing Chronic Low Back Pain (CLBP).

To assess differences in the microstructural improvement of brain fiber tracts between Minimally Invasive Parafascicular Surgery (MIPS) with NICO’s BrainPath and a conventional surgical approach following deep-seated tumor removal. The study aims to correlate these differences with associated clinical repercussions and patient functional outcomes that ultimately impact treatment decisions.

These results were recently published in Cancer Communications as the cover story, titled “Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.

Cyrano Therapeutics expects to enroll approximately 150 subjects in the FLAVOR trial, which is designed to assess the local nasal safety, tolerability, and effectiveness of CYR-064 as compared to placebo in the treatment of post-viral hyposmia over a six-month period. The FLAVOR trial is a multi-institutional prospective study being conducted at fifteen clinical sites in the United States.

Suvoda this new functionality offers sponsors of clinical drug trials improved drug supply management, delivering cost savings and helping companies to reduce their carbon footprint.